Compare GFL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFL | PEN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.0B |
| IPO Year | 2019 | 2015 |
| Metric | GFL | PEN |
|---|---|---|
| Price | $44.68 | $338.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $56.60 | ★ $357.33 |
| AVG Volume (30 Days) | ★ 1.5M | 665.3K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 4.52 |
| Revenue | N/A | ★ $1,403,665,000.00 |
| Revenue This Year | $7.27 | $14.20 |
| Revenue Next Year | $7.12 | $13.60 |
| P/E Ratio | ★ $5.95 | $75.34 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $40.83 | $221.26 |
| 52 Week High | $52.00 | $362.41 |
| Indicator | GFL | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 47.41 |
| Support Level | $42.34 | $338.08 |
| Resistance Level | $46.13 | $344.07 |
| Average True Range (ATR) | 1.14 | 2.27 |
| MACD | 0.22 | -0.77 |
| Stochastic Oscillator | 79.18 | 11.61 |
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.